Status: Not yet recruiting
Use of Immune Checkpoint Inhibitors in Patients With Advanced Hepatocellular Carcinoma : Efficacy and Outcomes
the Objectives of this study are: • Primary Objective: To prospectively evaluate overall survival (OS), ICI-specific survival (OS-ICI), and progression-free survival (PFS) in patients with advanced HCC treated with immune checkpoint inhibitors. the main question it aims to answer is: What are the clinical outcomes (overall survival, progression-free survival, and OS-ICIs) of immune checkpoint inhibitor therapy in patients with advanced hepatocellular carcinoma? Participants already taking immune checkpoint inhibitors as part of their regular medical care.
Participants needed: 75
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Ahmed Karam HelmyUpdated: Jan 6, 2026Locations: 2Duration: 12 Months
Eligibility criteria
Adults (≥18 years) with radiologically or histologically confirmed advanced HCC [+2]
Child-Pugh C liver function. [+3]